Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
2014 1
2021 1
2022 3
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Utilizing chemokines in cancer immunotherapy.
Märkl F, Huynh D, Endres S, Kobold S. Märkl F, et al. Trends Cancer. 2022 Aug;8(8):670-682. doi: 10.1016/j.trecan.2022.04.001. Epub 2022 Apr 29. Trends Cancer. 2022. PMID: 35501268 Review.
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.
Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, Müller K, Xu T, Dhoqina D, Märkl F, Robinson S, Sendelhofert A, Schulz H, Umut Ö, Kavaka V, Tsiverioti CA, Carlini E, Nandi S, Strzalkowski T, Lorenzini T, Stock S, Müller PJ, Dörr J, Seifert M, Cadilha BL, Brabenec R, Röder N, Rataj F, Nüesch M, Modemann F, Wellbrock J, Fiedler W, Kellner C, Beltrán E, Herold T, Paquet D, Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, Kobold S. Gottschlich A, et al. Among authors: markl f. Nat Biotechnol. 2023 Nov;41(11):1618-1632. doi: 10.1038/s41587-023-01684-0. Epub 2023 Mar 13. Nat Biotechnol. 2023. PMID: 36914885 Free PMC article.
T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.
Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou AD, Schübel M, Jobst J, Zhang T, Dörr J, Märkl F, Majed L, Müller PJ, May P, Gottschlich A, Tokarew N, Lücke J, Oner A, Schwerdtfeger M, Andreu-Sanz D, Grünmeier R, Seifert M, Michaelides S, Hristov M, König LM, Cadilha BL, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell RA, Cerezo-Wallis D, Tejedo C, Soengas MS, Bald T, Huber S, Endres S, Kobold S. Briukhovetska D, et al. Among authors: markl f. Immunity. 2023 Jan 10;56(1):143-161.e11. doi: 10.1016/j.immuni.2022.12.010. Immunity. 2023. PMID: 36630913 Free PMC article.
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
Märkl F, Benmebarek MR, Keyl J, Cadilha BL, Geiger M, Karches C, Obeck H, Schwerdtfeger M, Michaelides S, Briukhovetska D, Stock S, Jobst J, Müller PJ, Majed L, Seifert M, Klüver AK, Lorenzini T, Grünmeier R, Thomas M, Gottschlich A, Klaus R, Marr C, von Bergwelt-Baildon M, Rothenfusser S, Levesque MP, Heppt MV, Endres S, Klein C, Kobold S. Märkl F, et al. J Immunother Cancer. 2023 May;11(5):e006436. doi: 10.1136/jitc-2022-006436. J Immunother Cancer. 2023. PMID: 37208128 Free PMC article.
Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy.
Lorenzini T, Cadilha BL, Obeck H, Benmebarek MR, Märkl F, Michaelides S, Strzalkowski T, Briukhovetska D, Müller PJ, Nandi S, Winter P, Majed L, Grünmeier R, Seifert M, Rausch S, Feuchtinger T, Endres S, Kobold S. Lorenzini T, et al. Among authors: markl f. Br J Cancer. 2023 Sep;129(4):696-705. doi: 10.1038/s41416-023-02332-9. Epub 2023 Jul 4. Br J Cancer. 2023. PMID: 37400680 Free PMC article.
Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia.
Märkl F, Schultheiß C, Ali M, Chen SS, Zintchenko M, Egli L, Mietz J, Chijioke O, Paschold L, Spajic S, Holtermann A, Dörr J, Stock S, Zingg A, Läubli H, Piseddu I, Anz D, Minden MD, Zhang T, Nerreter T, Hudecek M, Minguet S, Chiorazzi N, Kobold S, Binder M. Märkl F, et al. Nat Commun. 2024 Feb 2;15(1):993. doi: 10.1038/s41467-024-45378-w. Nat Commun. 2024. PMID: 38307904 Free PMC article.
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Marcinek A, Brauchle B, Rohrbacher L, Hänel G, Philipp N, Märkl F, Strzalkowski T, Lacher SM, Udiljak D, Spiekermann K, Theurich S, Kobold S, Kischel R, James JR, Bücklein VL, Subklewe M. Marcinek A, et al. Among authors: markl f. Cancer Immunol Immunother. 2023 Jul;72(7):2499-2512. doi: 10.1007/s00262-023-03439-x. Epub 2023 Apr 11. Cancer Immunol Immunother. 2023. PMID: 37041225 Free PMC article.
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors.
Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, Vänttinen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Märkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Gottschlich A, Thomas M, Marr C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S, Kobold S. Cadilha BL, et al. Among authors: markl f. Sci Adv. 2021 Jun 9;7(24):eabi5781. doi: 10.1126/sciadv.abi5781. Print 2021 Jun. Sci Adv. 2021. PMID: 34108220 Free PMC article.
Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function.
Seifert M, Benmebarek MR, Briukhovetska D, Märkl F, Dörr J, Cadilha BL, Jobst J, Stock S, Andreu-Sanz D, Lorenzini T, Grünmeier R, Oner A, Obeck H, Majed L, Dhoqina D, Feinendegen M, Gottschlich A, Zhang J, Schindler U, Endres S, Kobold S. Seifert M, et al. Among authors: markl f. Br J Cancer. 2022 Dec;127(12):2175-2185. doi: 10.1038/s41416-022-02013-z. Epub 2022 Oct 20. Br J Cancer. 2022. PMID: 36266575 Free PMC article.
14 results